SEARCH:   Advanced

Blood, Vol. 114, Issue 14, 3024-3032, October 1, 2009 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features Blood Haferlach et al. 114: 3024 Supplemental materials for: Haferlach et al The authors from the Munich Leukemia Laboratory thank all physicians for sending bone marrow or blood samples to the laboratory for reference diagnosis and also for submitting clinical data. For those patients that were referred to our laboratory from centers of the AMLCG group, we listed the centers and investigators in order of the number of cases provided, in detail: University Hospital, Cologne (M. Hallek) Vivantes Hospital Neukölln, Berlin, (A. Grüneisen) Municipal Hospital, Gütersloh (C. Gropp,) St. Antonius Hospital, Eschweiler (P. Staib) Paracelsus Hospital, Osnabrück, (O. Koch) Campus Virchow Hospital, Berlin (B. Dörken), St. Johannes Hospital, Dortmund (H. Pielken) Municipal Hospital, Düren (M. Flaßhove) Municipal Hospital, Hagen (H. Eimermacher) Evangelian Hospital, Hamm (L. Balleisen) University Hospital, Mannheim (E. Lengfelder) St. Johannes Hospital, Duisburg (C. Aul) Maria Hilf Hospital, Mönchengladbach (D. Graeven) St. Marien Hospital, Siegen (W. Gassmann) St. Franziskus Hospital, Bielefeld (H.-J. Weh) Municipal Hospital Neuperlach, Munich (D. Fleckenstein) Municipal Hospital, Passau (Th. Südhoff) Helios Hospital, Berlin (W.-D. Ludwig) Vivantes Hospital, Berlin (E. Späth-Schwalbe) Knappschaft Hospital, Bottrop (G. Trenn) Municipal Hospital Center, Bremen (B. Hertenstein) Municipal Hospital Martha Maria, Halle/Saale (U. Haak) Municipal Hospital, Idar-Oberstein (A. Fauser) Municipal Hospital, Krefeld (Th. Frieling) Hospital Lippe-Lemgo, Lemgo (F. Hartmann) University Hospital, Regensburg (A. Reichle) Hospital Barmherzige Brüder, Regensburg (E.-D. Kreuser) Vinzenz Pallotti Hospital, Bergisch-Gladbach (S. Korsten) Knappschaft Hospital, Bochum (C. Teschendorf) Municipal Hospital, Kassel (M. Wolf) Municipal Hospital, Ludwigshafen (M. Uppenkamp) St. Walburga Hospital, Meschede (M. Schwonzen) The authors from the GIMEMA group thank all centers and investigators contributing to the GIMEMA LAM99P and GIMEMA/EORTC AML12 studies. The centers and investigators are listed in order of the number of cases provided: Istituto di Ematologia, Universitá “La Sapienza,” Roma (G. Meloni) Divisione di Ematologia, Ospedale “V. Cervello,” Palermo (F. Fabbiano) Divisione di Ematologia, Azienda USL di Pescara, Pescara (M. Sborgia) Cattedra di Ematologia, Bari, (V. Liso) Az. Osp. S.G. Moscati, Avellino (N. Cantore) Dipartimento di Emato-Oncologia, Azienda Ospedaliera “Bianchi-Melacrino-Morelli” Reggio Calabria (F. Nobile) Ospedale Ferrarotto-S. Bambino, Catania (F. Di Raimondo) Divisione di Ematologia e Oncologia Clinica, Catanzaro (D. Magro) Istituto di Ematologia, Universitá di Ancona, Ancona (P. Leoni) Istituto di Ematologia, Policlinico Monteluce, Perugia (A. Tabilio) Cattedra di Ematologia, Ospedale S. Chiara, Pisa (M. Petrini) Sezione di Medicina Interna, Oncologia ed Ematologia, Dipartimento Scienze Mediche, Oncologiche e Radiologiche, Modena (G. Torelli) Azienda Sanitaria Locale “Salerno 1,” Medicina Interna, Ematologia – Oncologia, Nocera Inferiore (A.M. D’Arco) Istituto di Ematologia, Universitá Federico II, Napoli (B. Rotoli) Divisione di Ematologia, Ospedale “S. Carlo,” Potenza (F. Ricciuti) Istituto di Ematologia, Policlinico “Gemelli,” Roma (S. Sica) Divisione di Ematologia, Ospedale Casa Sollievo della Sofferenza, S. Giovanni Rotondo (L. Melillo) Istituto di Ematologia, Ospedale “A. Businco,” Cagliari (E. Angelucci) Divisione di Ematologia, Ospedale “S. Giovanni Bosco,” Napoli (E. Miraglia) Divisione di Ematologia, Fondazione Centro “S. Raffaele del Monte Tabor,” Milano (L. Camba) Divisione di Ematologia, Azienda Ospedaliera Cremona, Cremona (S. Moranti) Divisione di Ematologia, Ospedale S. Eugenio, Roma (A. Venditti) Divisione Medica, Ospedale Maggiore, Lodi (G. Nalli) Divisione di Ematologia, Ospedale “S. Francesco,” Nuoro (A. Gabbas) Cattedra di Ematologia-CTMO, Universitá di Parma, Parma (V. Rizzoli) Divisione di Ematologia, Universitá di Sassari (F. Dore) Divisione di Ematologia, Ospedale SS. Antonio e Biagio, Alessandria (A. Levis) Azienda Ospedaliera “A. Di Summa,” Brindisi (G. Quarta) Divisione di Ematologia, Ospedale “S. Croce,” Cuneo (A. Gallamini) Sezione Ematologia, Dipartimento Scienze Biomediche, Arcispedale “S. Anna,” Ferrara (P-L Castaldi) Divisione di Ematologia, Ospedale di Messina (M. Brugiatelli). Files in this Data Supplement: Table S1. Top 500 differentially expressed probe sets (XLS, 1 MB) Figure S1. Survival curves of NPM1-mutated AML patients (FLT3−ITD+ versus FLT3−ITD−) from the Munich Leukemia Laboratory (JPG, 55.6 KB) - (Left) Overall survival (OS) is significantly shorter in NPM1-mutated cases with additional FLT3−ITD (FLT3−ITD+) (n=138) as compared to NPM1-mutated cases without FLT3−ITD mutation (FLT3−ITD−) (n=241) (median OS: not reached vs not reached; % alive at 2 years 50.9% vs 70.5%, p=0.015). (Right) Also event free survival (EFS) was significantly shorter in the NPM1-mutated/FLT3−ITD+ subgroup versus NPM1-mutated/FLT3−ITD− (11.6 months vs 17.0 months; p=0.045). Figure S2. Survival curves of NPM1-mutated/FLT3−ITD-positive subgroup AML patients (NK vs AK) from the Munich Leukemia Laboratory (JPG, 60.6 KB) - No difference in Overall Survival (OS) (left) and Event Free Survival (EFS) (right) was observed between NPM1-mutated AML with normal karyotype (NK) (n=123) or aberrant karyotype (AK) (n=15) in FLT3−ITD positive AML subgroup (median OS 21.1 months vs not reached; % alive at 2 years 47.5% vs 83.3%, p=0.245); and median EFS was 9.5 months vs 14.9 months (p=0.354). Figure S3. Survival curves of NPM1-mutated/FLT3−ITD-positive subgroup AML patients (NK vs AK) from the GIMEMA LAM99P and GIMEMA/EORTC AML12 trials (JPG, 49.6 KB) - (A) No significant differences in overall survival are observed between NPM1-mutated/FLT3−ITD-positive AML with normal (n=55) and aberrant (n=6) karyotype (p=0.783); (B) No significant differences in event free survival are observed between NPM1-mutated/FLT3−ITD-positive AML with normal (n=55) and aberrant (n=6) karyotype (p=0.643). This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020